埃索美拉唑在治疗胃食管反流性疾病效果如何？

How effective is esomeprazole in treating gastroesophageal reflux disease? This trial evaluates the clinical effects of esomeprazole (Nexium) and omeprazole combined with mosapride in the treatment of gastroesophageal reflux disease.

The trial selected 107 patients and randomly divided them into the esomeprazole (Nexium) combined with mosapride group or the omeprazole combined with mosapride group. Esomeprazole combined with mosapride group: oral esomeprazole 20 mg, 2 times/d, 1 dose in the morning and evening; mosapride 5 mg, 3 times/d. Omeprazole combined with mosapride group: Oral omeprazole 20 mg, 2 times/d, once in the morning and evening; Mosapride 5 mg, 3 times/d, the treatment course for both groups was 8 weeks. Results The total effective rate of clinical symptom improvement in the esomeprazole (Nexium) combined with mosapride group was significantly higher than that of the omeprazole combined with mosapride group at 4 and 8 weeks of treatment (P<0.05). After 8 weeks of treatment, the total effective rate of esophageal mucosal healing in the two groups was 94.5% and 71.2% respectively, and the esomeprazole group was significantly more effective than the omeprazole group. Conclusion: Esomeprazole (Nexium) combined with mosapride has a higher cure rate in the treatment of gastroesophageal reflux disease, and its efficacy is better than that of omeprazole combined with mosapride.

The therapeutic effect of esomeprazole (Nexium, Nexium) is significant, but the medical companions remind that esomeprazole (Nexium, Nexium) affects the pharmacokinetics of other drugs. For those drugs whose absorption process is affected by gastric acid, during esomeprazole treatment, due to the decrease in gastric acid, the absorption of these drugs can be increased or reduced. As with other oxynta suppressants or antacids, the absorption of ketoconazole and itraconazole may be reduced during treatment with esomeprazole (Nexium). Esomeprazole inhibits CYP2C19, the main metabolizing enzyme of esomeprazole.